Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Ding, Qingjie, Zhang, Zhuming, Liu, Jin-Jun, Jiang, Nan, Zhang, Jing, Ross, Tina M., Chu, Xin-Jie, Bartkovitz, David +9 more·2013·Journal of Medicinal Chemistry
DOI 10.1021/jm400487c

Cited by (617)

Items 301–400 of 617

  1. Biochemical properties of Schiff bases derived from FDA-approved sulfa drugs: Synthesis, ADME/molecular docking studies, and anticancer activity
    Sali̇ha Alyar, Hami̇t Alyar, Ümmühan Özdemir Özmen, Okan Aktaş, Kelime Erdem · 2023 · Journal of Molecular Structure
  2. 5-Methoxyisatin N(4)-Pyrrolidinyl Thiosemicarbazone (MeOIstPyrd) Restores Mutant p53 and Inhibits the Growth of Skin Cancer Cells, In Vitro
    Nerina Shahi, Paras Nath Yadav, Upendra Chaudhary, Mohd Saad, Kuldeep Mahiya, Arif Ali Khan, Syed Shafi, Yuba Raj Pokharel · 2023 · ACS Omega
  3. Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-b] indole Derivatives as Broad-Spectrum Potent Anticancer Agents
    Shivaputra A. Patil, James K. Addo, Hemantkumar S. Deokar, Shan Sun, Jin Wang, Wei Li, D. Parker Suttle, Wei Wang, Ruiwen Zhang, John K. Buolamwini · 2017 · Drug Designing Open Access
  4. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors
    John J. Nemunaitis, Annie Young, Samuel Ejadi, Wilson H. Miller, Lin-Chi Chen, GWEN L. NICHOLS, Steven D. Blotner, Faye Vazvaei, Jianguo Zhi, Albiruni R. Abdul Razak · 2018 · Cancer Chemotherapy and Pharmacology
  5. Established, emerging and elusive molecular targets in the treatment of lung cancer
    Jean‐Nicolas Gallant, Christine Marie Lovly · 2018 · The Journal of Pathology
  6. Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
    Geoffrey L. Uy, Sarit E. Assouline, Anne-Marie Young, Steven D. Blotner, Brian Higgins, Lin-Chi Chen, Karen W L Yee · 2020 · Investigational New Drugs
  7. Targeting p53-MDM2 interactions to identify small molecule inhibitors for cancer therapy: beyond “Failure to rescue”
    Prosper Obed Chukwuemeka, Haruna Isiyaku Umar, Opeyemi Iwaloye, Oluwaseyi Matthew Oretade, Christopher Busayo Olowosoke, Michael Omoniyi Elabiyi, Festus Omotere Igbe, Oyeyemi Janet Oretade, Joy Oseme Eigbe, Funmilayo Janet Adeojo · 2021 · Journal of Biomolecular Structure and Dynamics
  8. Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities
    Aiman B. Awan, Maryiam Jama Ali Osman, Omar M. Khan · 2025 · Cells
  9. Repurposing MDM2 inhibitor RG7388 for TP53-mutant NSCLC: a p53-independent pyroptotic mechanism via ROS/p-p38/NOXA/caspase-3/GSDME axis
    Gaoyan Tang, Xuelei Cao, Jiaqi Chen, Fu Hui, Na Xu, Yiqing Jiang, Hongmin Lu, Haifeng Xiao, Xiuming Liang, Mingzhe Ma et al. · 2025 · Cell Death and Disease
  10. Cancer-associated fibroblast secreted DKK1 promotes the immunosuppressive tumor microenvironment and colorectal cancer resistance to chemotherapy
    Zhijie Yin, Yuning Zhou, Xudong Zhu, Ryan A. Goettl, Chi Wang, Heidi L. Weiss, Bernard Mark Evers, Qingding Wang · 2025 · Cancer Letters
  11. Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients
    Giorgio Zauli, Veronica Tisato, Paola Secchiero · 2020 · Frontiers in Pharmacology
  12. Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer
    Neha Bhatia, Rakesh Khator, Swanand Kulkarni, Yogesh Singh, Pradeep Kumar, Suresh Thareja · 2022 · Current Medicinal Chemistry
  13. Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
    Michael P. Ludwig, Matthew D. Galbraith, Neetha Paul Eduthan, Amanda A. Hill, Michael R. Clay, Cristiam Moreno Tellez, Breelyn Ann Wilky, ANTHONY D. ELIAS, Joaquin Maximiliano Espinosa, Kelly D. Sullivan · 2023 · Cancer Research
  14. Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated PlatinumIV Complexes as Potent Antitumor Agents
    Wei Liu, Yi Ma, Youyou He, Yanhong Liu, Zhongjie Guo, Jin He, Xiaodong Han, Yujiao Hu, Muqiong Li, Ru Jiang et al. · 2024 · Journal of Medicinal Chemistry
  15. Harnessing p53 for targeted cancer therapy: new advances and future directions
    Zdeněk Andrysík, Joaquin Maximiliano Espinosa · 2025 · Transcription
  16. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors
    Albiruni R. Abdul Razak, Wilson H. Miller, Geoffrey L. Uy, Steven D. Blotner, Anne-Marie Young, Brian Higgins, Lin-Chi Chen, Lia Gore · 2019 · Investigational New Drugs
  17. Small-molecule modulation of p53 protein-protein interactions
    Ave Kuusk, Helen Boyd, Hongming Chen, Christian Ottmann · 2020 · Biological Chemistry
  18. Synthesis and Biological Evaluation of S-, O- and Se-Containing Dispirooxindoles
    Maxim E. Kukushkin, Vladimir M. Novotortsev, Vadim Filatov, Yan A. Ivanenkov, Dmitry Aleksandrovich Skvortsov, Mark S. Veselov, Radik R. Shafikov, Anna A. Moiseeva, N. Zyk, Alexander G. Majouga et al. · 2021 · Molecules
  19. A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [14C]-labeled idasanutlin and an intravenous tracer dose of [13C]-labeled idasanutlin in a single cohort of patients with solid tumors
    Zsuzsanna Pápai, Lin-Chi Chen, Daniel Da Costa, Steven D. Blotner, Faye Vazvaei, Michelle Gleave, Russell Jones, Jianguo Zhi · 2019 · Cancer Chemotherapy and Pharmacology
  20. Potential of rescue and reactivation of tumor suppressor p53 for cancer therapy
    Emi Hibino, Hidekazu Hiroaki · 2022 · Biophysical Reviews
  21. An update patent review of MDM2–p53 interaction inhibitors (2019–2023)
    Aleksandra Twarda‐Clapa · 2024 · Expert Opinion on Therapeutic Patents
  22. Enantioselective Reaction Using Palladium Pincer Complexes with C2-Symmetric Chiral Bis(imidazoline)s
    Shuichi Nakamura · 2015 · Journal of Synthetic Organic Chemistry Japan
  23. Upregulation of p53 through induction of MDM2 degradation: Anthraquinone analogs
    Alexander B. Draganov, Xiaoxiao Yang, Abiodun Anifowose, Ladie Kimberly De La Cruz, Chaofeng Dai, Nanting Ni, Weixuan Chen, Zeus A. De los Santos, Lubing Gu, Muxiang Zhou et al. · 2019 · Bioorganic & Medicinal Chemistry
  24. Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
    Li Jun Ding, Zhiping Zhang, Chenhong Zhao, Lei Chen, Zhiqiang Chen, Jie Zhang, Yaxian Liu, Yesen Nie, Yanzhi He, Kai Liao et al. · 2021 · Journal of Experimental & Clinical Cancer Research
  25. Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer
    Ana Maria Montagut, Marc Armengol, Gema Gorjón-de-Pablo, Roger Estrada‐Tejedor, José Ignacio Borrell, Gaël Roué · 2022 · Seminars in Cell and Developmental Biology
  26. Discovery of new low-molecular-weight p53–Mdmx disruptors and their anti-cancer activities
    Shinichi Uesato, Yoshihiro Matsuura, Saki Matsue, Takaaki Sumiyoshi, Yoshiyuki Hirata, Suzuho Takemoto, Yasuyuki Kawaratani, Yu‐suke Yamai, Kyoji Ishida, Tsutomu Sasaki et al. · 2016 · Bioorganic & Medicinal Chemistry
  27. Mimicking Intermolecular Interactions of Tight Protein–Protein Complexes for Small‐Molecule Antagonists
    David Daqiang Xu, Khuchtumur Bum‐Erdene, Yubing Si, Donghui Zhou, Mona K. Ghozayel, Samy O. Meroueh · 2017 · ChemMedChem
  28. Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting
    Bérengère Dadone‐Montaudié, Audrey Laroche‐Clary, Aline Mongis, Emmanuel Chamorey, Ilaria Di Mauro, Vanessa Chaire, Pascal Finetti, Renaud Schiappa, François Le Loarer, Isabelle Birtwisle‐Peyrottes et al. · 2020 · Cancers
  29. STING-mediated degradation of IFI16 negatively regulates apoptosis by inhibiting p53 phosphorylation at serine 392
    Dapei Li, Lifen Xie, Zigang Qiao, Sanyue Mai, Jingfei Zhu, Fan Zhang, Shengchuan Chen, Liang Li, Fangrong Shen, Yanghua Qin et al. · 2021 · Journal of Biological Chemistry
  30. Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia
    Angelo Aguilar, Jiuling Yang, Yangbing Li, Donna McEachern, Liyue Huang, Stevenchoukry Razzouk, Shaomeng Wang · 2024 · Journal of Medicinal Chemistry
  31. Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML
    Steven D. Blotner, Lin-Chi Chen, Cristiano Ferlini, Jianguo Zhi · 2018 · Cancer Chemotherapy and Pharmacology
  32. Catalytic Enantioselective Formal Synthesis of MDM2 Antagonist RG7388 and Its Analogues
    Xuejie Zou, Wu‐Lin Yang, Jing‐Yan Zhu, Wei‐Ping Deng · 2020 · Chinese Journal of Chemistry
  33. The Exon Junction Complex Core Represses Cancer-Specific Mature mRNA Re-splicing: A Potential Key Role in Terminating Splicing
    Yuta Otani, Ken‐ichi Fujita, Toshiki Kameyama, Akila Mayeda · 2021 · International Journal of Molecular Sciences
  34. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors
    Irina N. Alimova, Dong Wang, Etienne P. Danis, Angela M. Pierce, Andrew M. Donson, Natalie Julie Serkova, Krishna P.C. Madhavan, Senthilnath Lakshmanachetty, Ilango Balakrishnan, Nicholas K. Foreman et al. · 2022 · International Journal of Oncology
  35. Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genes
    Qianqian Wang, Jun Li, Jing Zhu, Jiaqi Mao, Chao Duan, Xiao Liang, Lingyun Zhu, Mengyan Zhu, Zhihong Zhang, Fan Lin et al. · 2022 · Clinical and Translational Medicine
  36. p53–MDM2 and MDMX Antagonists
    Constantinos G. Neochoritis, Natalia Estrada‐Ortiz, Kareem Khoury, Alexander S. S. Dömling · 2014 · Annual reports in medicinal chemistry
  37. Quinofuracins A–E, Produced by the Fungus Staphylotrichum boninense PF1444, Show p53-Dependent Growth Suppression
    Daisuke Tatsuda, Isao Momose, Tetsuya Someno, Ryûichi Sawa, Yumiko Kubota, Masatomi Iijima, Takao Kunisada, Takumi Watanabe, Masakatsu Shibasaki, Akio Nomoto · 2015 · Journal of Natural Products
  38. TP53in adult acute lymphoblastic leukemia
    Silvia Salmoiraghi, Alessandro Rambaldi, Orietta Spinelli · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
  39. A Computational Investigation of Small-Molecule Engagement of Hot Spots at Protein–Protein Interaction Interfaces
    David Daqiang Xu, Yubing Si, Samy O. Meroueh · 2017 · Journal of Chemical Information and Modeling
  40. A fluorinated indole‐based MDM 2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells
    Łukasz Skalniak, Aleksandra Twarda‐Clapa, Constantinos G. Neochoritis, Ewa Surmiak, Monika Machula, Aneta Wiśniewska, Beata Łabuzek, Ameena Mohamed Ali, Sylwia Krzanik, Grzegorz Dubin et al. · 2019 · FEBS Journal
  41. Systematic ‘foldamerization’ of peptide inhibiting p53-MDM2/X interactions by the incorporation of trans- or cis-2-aminocyclopentanecarboxylic acid residues
    Paulina Fortuna, Aleksandra Twarda‐Clapa, Łukasz Skalniak, Katarzyna Ożga, Tad A. Holak, Łukasz Berlicki · 2020 · European Journal of Medicinal Chemistry
  42. Discovery of 1-arylpyrrolidone derivatives as potent p53–MDM2 inhibitors based on molecule fusing strategy
    Jin Li, Yuelin Wu, Zizhao Guo, Chunlin Zhuang, Jianzhong Yao, Guoqiang Dong, Zhiliang Yu, Xiao Min, Shengzheng Wang, Yang Liu et al. · 2014 · Bioorganic & Medicinal Chemistry Letters
  43. Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors
    Jakub Stefaniak, Andrew M. Lewis, Daniel Conole, Sébastien R. G. Galan, Carole J. R. Bataille, Graham M. Wynne, Maria Paola Castaldi, Thomas Lundbäck, Angela J. Russell, K. Huber · 2018 · ACS Chemical Biology
  44. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
    Loredana Urso, Ilaria Cavallari, Micol Silic‐Benussi, Lorena Biasini, Giulia Zago, Fiorella Calabrese, PierFranco Conte, Vincenzo Ciminale, Giulia Pasello · 2017 · Oncotarget
  45. Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition
    Erhan Aptullahoğlu, Carmela Ciardullo, Jonathan Peter Wallis, Helen J. Marr, Scott R Marshall, Nick P. Bown, Elaine Willmore, John Lunec · 2023 · International Journal of Molecular Sciences
  46. Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC Inhibitor Entinostat Enhances their Therapeutic Potential Through Synergistic Antitumor Effects and Reduction of Systemic Toxicity
    Anas Ibrahim Abed, Michelle K. Greene, Alhareth A. Alsa’d, Andrea Lees, Andrew Hindley, Daniel B. Longley, Simon S. McDade, Christopher J. Scott · 2024 · Molecular Pharmaceutics
  47. MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors
    Katrine Ingelshed, Marit Martina Melssen, Pavitra Kannan, Arun Chandramohan, Anthony W. Partridge, Long Jiang, Fredrik Wermeling, David Philip Lane, Marika Nestor, Diana Spiegelberg · 2024 · iScience
  48. Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology
    Eran Zimran, Maria Zingariello, Maria Teresa Bochicchio, Claudio Bardelli, Anna Ritá Migliaccio · 2019 · F1000Research
  49. Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway
    Yingying Cui, Jing Zhou, Fengnian Rong · 2020 · Biochemical and Biophysical Research Communications
  50. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches
    Nicole Renee Grieselhuber, Alice S. Mims · 2021 · Current Hematologic Malignancy Reports
  51. A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3)
    Dylan R. Rivas, Mark Vincent C. dela Cerna, Caroline N. Smith, Shilpa Sampathi, Blaine G. Patty, Donghan Lee, Jessica S. Blackburn · 2021 · Scientific Reports
  52. Functional roles of E3 ubiquitin ligases in prostate cancer
    Yiting Zhao, Jinyun Li, Jun Chen, Meng Ye, Xiaofeng Jin · 2022 · Journal of Molecular Medicine
  53. Core modification of substituted piperidines as Novel inhibitors of HDM2–p53 protein–protein interaction
    Weidong Pan, Brian R. Lahue, Yao Ma, Latha G. Nair, Gerald W. Shipps, Yaolin Wang, Ronald J. Doll, Stephane L. Bogen · 2014 · Bioorganic & Medicinal Chemistry Letters
  54. Mapping of Protein-Protein Interactions: Web-Based Resources for Revealing Interactomes
    Branislava Gemović, Neven Šumonja, Radoslav S. Davidović, Vladimir Perović, Nevena Veljković · 2018 · Current Medicinal Chemistry
  55. 1,3‐Dipolar Cycloaddition of 3‐Chromonyl‐Substituted Glycine Imino Esters with Arylidenes and in situ Diastereodivergent via Retrocycloaddition
    Mohammed F. Radwan, Elghareeb E. Elboray, Hemat Mohamed Dardeer, Yusuke Kobayashi, Takumi Furuta, Shohei Hamada, Toshifumi Dohi, Moustafa F. Aly · 2023 · Chemistry - An Asian Journal
  56. Design, synthesis and structure–activity relationship of 4,5-dihydropyrrolo[3,4- c ]pyrazol-6(1 H )-ones as potent p53-MDM2 inhibitors
    Wei-Huang Zhou, Xiguo Xu, Jin Li, Xiao Min, Jianzhong Yao, Guoqiang Dong, Chunlin Zhuang, Zhenyuan Miao, Wannian Zhang · 2016 · Chinese Chemical Letters
  57. Ynamide Coupling Reagent for the Chemical Cross-Linking of Proteins in Live Cells
    Shengrong Li, Chengjun Zhu, Qian Zhao, Zhimin Zhang, Pinghua Sun, Zhengqiu Li · 2023 · ACS Chemical Biology
  58. Reflexive Chirality Transfer (RCT): Asymmetric 1,3-Dipolar Cycloaddition of α-Amino Acid Schiff Base with Nonchiral Copper Catalyst
    Kazuhiro Morisaki, Yuto Furuki, Rento Kousaka, Serika Nagai, Yoshihiro Oonishi, Yoshihiro Sato · 2025 · Journal of the American Chemical Society
  59. The R882H substitution in the human de novo DNA methyltransferase DNMT3A disrupts allosteric regulation by the tumor supressor p53
    Jonathan E. Sandoval, Norbert O. Reich · 2019 · Journal of Biological Chemistry
  60. Upregulation of p53 through induction of MDM2 degradation: Amino acid prodrugs of anthraquinone analogs
    Abiodun Anifowose, Zhengnan Yuan, Xiaoxiao Yang, Zhixiang Pan, Yueqin Zheng, Zhongwei Zhang, Binghe Wang · 2019 · Bioorganic & Medicinal Chemistry Letters
  61. The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
    Katrine Ingelshed, Diana Spiegelberg, Pavitra Kannan, Linnéa Påvénius, Jessica Hacheney, Long Jiang, Silke Eisinger, Danai Lianoudaki, Dilraj Lama, Francisca A. Castillo et al. · 2022 · Cancer Research Communications
  62. Decoding the Role of MDM2 as a Potential Ubiquitin E3 Ligase and Identifying the Therapeutic Efficiency of Alkaloids against MDM2 in Combating Glioblastoma
    Sudhanshu Sharma, Pravir Kumar · 2023 · ACS Omega
  63. TP53 and its Regulatory Genes as Prognosis of Cutaneous Melanoma
    Safir Ullah Khan, Zahid Ullah, Hadia Shaukat, Shiza Unab, Saba Jannat, Waqar Ali, Amir Ali, Muhammad Irfan, Muhammad Fiaz Khan, Rodolfo Daniel Cervantes‐Villagrana · 2023 · Cancer Informatics
  64. Searching for Dual Inhibitors of the MDM 2‐p53 and MDMX ‐p53 Protein–Protein Interaction by a Scaffold‐Hopping Approach
    Andrey V. Zaytsev, Barry Dodd, Matteo Magnani, Chiara Ghiron, Bernard T. Golding, Roger J. Griffin, Junfeng Liu, Xiaohong Lü, Iolanda Micco, David R. Newell et al. · 2014 · Chemical Biology & Drug Design
  65. The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
    Cosimo Lobello, Vasilis Bikos, Andrea Janíková, Šárka Pospı́šilová · 2018 · Cancers
  66. Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs
    Longyuan Gong, Danrui Cui, Xiufang Xiong, Yongchao Zhao · 2020 · Advances in experimental medicine and biology
  67. Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment
    Xiuzhen Zhang, Tong Meng, Shuaishuai Cui, Ling Feng, Dongwu Liu, Qiuxiang Pang, Ping Wang · 2021 · Frontiers in Oncology
  68. MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3
    Joshua P. Smalley, Shaun M. Cowley, James T. Hodgkinson · 2023 · ACS Medicinal Chemistry Letters
  69. Chemical modulation of transcription factors
    Bianca M. Wiedemann, Jörn Weisner, Daniel Rauh · 2018 · MedChemComm
  70. A BRET-based assay reveals collagen–Hsp47 interaction dynamics in the endoplasmic reticulum and small-molecule inhibition of this interaction
    Shinya Ito, Masazumi Saito, Masahito Yoshida, Koh Takeuchi, Takayuki Doi, Kazuhiro Nagata · 2019 · Journal of Biological Chemistry
  71. Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors
    Dongjuan Si, Huijuan Luo, Xiaomeng Zhang, Kundi Yang, Hongmei Wen, Jian Li, Jian Li · 2021 · Bioorganic Chemistry
  72. Differential mechanisms involved in RG-7388 and Nutlin-3 induced cell death in SJSA-1 osteosarcoma cells
    Natarajan, Umamaheswari, Venkatesan, Thiagarajan, Dhandayuthapani, Sivanesan, Dondapatti, Priya, Rathinavelu, Appu · 2020 · Cellular Signalling
  73. Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies
    Klaudia Giercuszkiewicz-Haśnik, BEATA IZABELA MORAK-MŁODAWSKA, Małgorzata Jeleń · 2026 · Molecules
  74. Strong activation of p53 by actinomycin D and nutlin-3a overcomes the resistance of cancer cells to the pro-apoptotic activity of the FAS ligand
    Barbara Łasut-Szyszka, Agnieszka Gdowicz‐Kłosok, Małgorzata Krześniak, Magdalena Głowala‐Kosińska, Agnieszka Będzińska, Marek Rusin · 2024 · APOPTOSIS
  75. N-Terminal Targeting of Regulator of G Protein Signaling Protein 2 for F-Box Only Protein 44–Mediated Proteasomal Degradation
    Harrison J. McNabb, Stephanie González, Christine S. Muli, Benita Sjögren · 2020 · Molecular Pharmacology
  76. P53 upregulation by USP7-engaging molecular glues
    Zhaoyang Li, Ziying Wang, Chao Zhong, Hang Zhang, Rui Liu, Ping An, Z. Ma, Junmei Lü, Chengfang Pan, Zhaolin Zhang et al. · 2024 · 中国科学通报：英文版
  77. Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma
    Frank Herting, Thomas Friess, Pablo Umaña, Steven A. Middleton, Christian Klein · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
  78. p38 but not p53 is responsible for UVA-induced MCPIP1 expression
    Łukasz Skalniak, Marta Smejda, Agnieszka Cierniak, Anna Adamczyk, Piotr Konieczny, Ewelina Madej, Agnieszka Wolnicka-Głubisz · 2017 · Mechanisms of Ageing and Development
  79. TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response
    Chiao‐En Wu, Tsin Shue Koay, Yi-Hsuan Ho, Penny E. Lovat, John Lunec · 2019 · Cancer Cell International
  80. Perspectives on drug discovery strategies based on IDPs
    Gustavo Fuertes, Laura Nevola, Santi Esteban-Martín · 2019 · Elsevier eBooks
  81. The clinical development of p53-reactivating drugs in sarcomas – charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins
    Swethajit Biswas, Emma Killick, Aart G. Jochemsen, John Lunec · 2014 · Expert Opinion on Investigational Drugs
  82. The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer
    Ze Rong, Kaifeng Zheng, Jun Chen, Xiaofeng Jin · 2024 · Journal of Cancer Research and Clinical Oncology
  83. Targeting p53 activation: Recent therapeutic advances in cancer and diabetic macular edema
    Zhiyi Wang, Shijie Zhang, Irakoze Loïca Mélita, Yujun Zhao · 2025 · European Journal of Medicinal Chemistry
  84. Identification of a Structural Determinant for Selective Targeting of HDMX
    Yael Ben‐Nun, Hyuk‐Soo Seo, Edward P. Harvey, Zachary J. Hauseman, Thomas E. Wales, Catherine E. Newman, Ann M. Cathcart, John R. Engen, Sirano Dhe‐Paganon, Loren D. Walensky · 2020 · Structure
  85. p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors
    Wenfang Li, Leader Alfason, Can Huang, Yu Rong Tang, Qiu Li, Makoto Miyagishi, Shourong Wu, Vivi Kasim · 2022 · Acta Pharmacologica Sinica
  86. Enantioselective Synthesis and Biological Evaluation of Pyrrolidines Bearing Quaternary Stereogenic Centers
    Han‐Yue Qiu, Zhuanzhuan Du, Yankun Zhao, Shan Yuan, Song Xi, Tao Zhou, Jiao Yang, Changhui Zhang, Yang Xiong, Yi Xia et al. · 2023 · Journal of Medicinal Chemistry
  87. New Compound Classes: Protein–Protein Interactions
    Christian Ottmann · 2015 · Handbook of experimental pharmacology
  88. Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans
    Kelli Glenn, Li J. Yu, Micaela B. Reddy, Adrian J. Fretland, Neil John Parrott, Sazzad Hussain, Mary Palacios, Faye Vazvaei, Jianguo Zhi, Dietrich Tuerck · 2015 · Xenobiotica
  89. Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
    Kelly M. Thayer, George A. Beyer · 2016 · PLoS ONE
  90. Targeting a helix-in-groove interaction between E1 and E2 blocks ubiquitin transfer
    Ann M. Cathcart, Gregory H. Bird, Thomas E. Wales, Henry David Herce, Edward P. Harvey, Zachary J. Hauseman, Catherine E. Newman, Utsarga Adhikary, Michelle S. Prew, Tun Oo et al. · 2020 · Nature Chemical Biology
  91. Induction of apoptosis in Ehrlich ascites tumour cells via p53 activation by a novel small-molecule MDM2 inhibitor – LQFM030
    Mariana Flávia da Mota, Alane P. Cortez, Polyana Lopes Benfica, Bruna dos Santos Rodrigues, Thalyta F Castro, Larissa Matuda Macedo, Carlos H. Castro, Luciano Morais Lião, Flávio Silva de Carvalho, Luiz Antônio Soares Romeiro et al. · 2016 · Journal of Pharmacy and Pharmacology
  92. Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration
    Sol Jeong, Jae‐Kook Cha, Wasim Ahmed, Jaewan Kim, Minsup Kim, Kyung Tae Hong, Wonji Choi, Sunjoo Choi, Tae Hyeon Yoo, Hyun‐Ju An et al. · 2025 · Advanced Science
  93. TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
    Eric D. Eisenmann, Jack C. Stromatt, Sydney Fobare, Kevin M. Huang, Daelynn R. Buelow, Shelley J. Orwick, Jae Yoon Jeon, Robert H. Weber, Bill Larsen, Alice S. Mims et al. · 2022 · Cancers
  94. Nutlin‐3 treatment spares cisplatin‐induced inhibition of bone healing while maintaining osteosarcoma toxicity
    Kimo C. Stine, Elizabeth C. Wahl, Lichu Liu, Robert A. Skinner, Jaclyn VanderSchilden, R. Clay Bunn, Corey O Montgomery, James Aronson, David L. Becton, Richard W. Nicholas et al. · 2016 · Journal of Orthopaedic Research®
  95. Selective Inhibitors of T Cell Receptor Recognition of Antigen–MHC Complexes for Rheumatoid Arthritis
    Francesco Ria, Davide Pirolli, Gabriele Di Sante, Benedetta Righino, Elisa Gremese, Jacopo Gervasoni, Chiara Nicolò, Bruno Giardina, Gianfranco Ferraccioli, Maria Cristina De Rosa · 2019 · ACS Medicinal Chemistry Letters
  96. Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia
    Şeyda GÜNGÖRDÜ, Erhan Aptullahoğlu · 2024 · Investigational New Drugs
  97. Lead discovery and chemical biology approaches targeting the ubiquitin proteasome system
    Favour A. Akinjiyan, Seth Carbonneau, Nathan T. Ross · 2017 · Bioorganic & Medicinal Chemistry Letters
  98. Cell‐ and Tissue‐Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin
    Dongsheng Zhu, Haijun Guo, Yu Chang, Yun Ni, Lin Li, Zhi‐Min Zhang, Piliang Hao, Yong Xu, Ke Ding, Zhengqiu Li · 2018 · Angewandte Chemie
  99. LIN28B inhibition sensitizes cells to p53-restoring PPI therapy through unleashed translational suppression
    Jiahao Shi, Xiaoliang Jin, Yihao Wang, Tianyu Zhu, Dongmei Zhang, Qian Li, Xiaomin Zhong, Yaqi Deng, Jianfeng Shen, Xianqun Fan · 2022 · Oncogenesis
  100. Synthesis and biological evaluation of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold
    Najah G. Albadari, Yang Xie, Tao Liu, Rui Wang, Lubing Gu, Muxiang Zhou, Zhongzhi Wu, Wěi Li · 2023 · European Journal of Medicinal Chemistry